Artiva Biotherapeutics, Inc. (ARTV) Current Ratio
- Current ratio · latest quarter: Value 24.16×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 24.16× | Current assets / current liabilities. $352.28M ÷ $14.58M ≈ 24.16× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 352.28M USD | Assets, Current |
| Current obligations | 14.58M USD | Liabilities, Current |
| Cash and equivalents | 301.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.39M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $352.28M | $14.58M | $301.45M | (m) | (m) | (m) | $1.39M | (m) | 24.16× |
| 2026-03-31 | $88.74M | $10.88M | $20.95M | (m) | (m) | (m) | $2.29M | (m) | 8.16× |
| 2025-12-31 | $112.67M | $13.09M | $26.70M | (m) | (m) | (m) | $355.00K | (m) | 8.61× |
| 2025-09-30 | $129.52M | $11.12M | $25.51M | (m) | (m) | (m) | $848.00K | (m) | 11.65× |
| 2025-06-30 | $149.07M | $10.77M | $28.47M | (m) | (m) | (m) | $1.22M | (m) | 13.84× |
| 2025-03-31 | $170.00M | $12.20M | $30.40M | (m) | (m) | (m) | $2.04M | (m) | 13.93× |
| 2024-12-31 | $188.63M | $12.25M | $40.23M | (m) | (m) | (m) | $1.12M | (m) | 15.39× |
| 2024-09-30 | $150.56M | $13.29M | $55.88M | (m) | $569.00K | (m) | $1.22M | (m) | 11.33× |
| 2024-06-30 | $49.75M | $10.83M | $34.25M | (m) | $569.00K | (m) | $823.00K | (m) | 4.59× |
| 2023-12-31 | $79.82M | $12.23M | $53.50M | (m) | $1.03M | (m) | $614.00K | (m) | 6.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |